James Udelson, MD, is the chief of the division of cardiology at Tufts Medical Center.

Tovinontrine, an investigative oral phosphodiesterase 9 (PDE9) inhibitor, has successfully reduced NT-proBNP in patients with 

heart failure with reduced ejection fraction (HFrEF)

, based on results from the phase 2 Cycle-1-REF trial.

Tovinontrine Reduces NT-proBNP in HFrEF, May Have Greater Benefit at Smaller Doses

Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026

 in Phoenix, Arizona, by James Udelson, MD, chief of the division of cardiology at Tufts Medical Center. At the meeting, Udelson met with 

 to discuss the trial, its findings, and the implications for this highly treated patient population.

“In contemporary practice, whether it’s the development of drugs or devices, you really have to show that your new drug or new device does something good on top of well-treated patients,” Udelson said. “If people are poorly treated and you show that a new drug helps them in some way, this community, and I myself, would be skeptical of that.”

Cycle-1-REF was a phase 2, randomized, double-blind, placebo-controlled, dose-finding study aiming to assess tovinontrine’s efficacy in patients with chronic HFrEF. Patients were eligible for enrollment if they had evidence supporting a diagnosis of clinical HF with New York Heart Association (NYHA) functional class 2 or 3, and an ejection fraction (EF) ≤40%, among other criteria. Patients with EF >40%, evidence of recent HF exacerbation, or major cardiovascular surgery within 60 days of screening, among other criteria, were excluded.

Patients were randomly assigned to a low (2.5 mg), medium (25 mg), or high (50 mg) dose of tovinontrine or placebo, all of which were administered orally and on top of guideline-directed medical therapy. The primary endpoint was the percent change in plasma NT-proBNP from baseline to week 12. Secondary outcomes included change in urine and plasma cGMP from baseline, the ratio between the percent change in urine and plasma cGMP versus NT-proBNP, and the change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CCS).

A total of 529 patients were included in the Cycle-1-REF trial, with 53 assigned to the low dose, 159 to the medium dose, 159 to the high dose, and 158 to placebo. These patients had a mean age of 69 +/- 10 years and a mean EF of 32% +/- 6%. Median NT-proBNP was 1473 at baseline, and 44% of patients had NYHA class 3 HF. Of the included patients, 93 were on sacubitril/valsartan or RASi at baseline, while 79 were on SGLT2 inhibitors or MRAs.

At 12 weeks, the patients receiving 2.5 mg of tovinontrine saw a mean change of -14.1% in NT-proBNP (95% CI, -27.2 to 1.3; 

 = .07), while the 25 mg arm saw a mean reduction of -10.8% (95% CI, -20.6 to 0.1; 

 = .05) and the 50 mg arm had a reduction of -4.4 (95% CI, -14.9 to 7.5; 

 = .45). Mean percent change in plasma cGMP was 6% in the 2.5 mg arm, 7% in the 25 mg arm, 6% in the 50 mg arm, and -9% in the placebo arm. These results led Udelson and colleagues to hypothesize that a threshold of myocardial cGMP elevation exists above which counter-regulatory mechanisms could limit downstream signaling.

In a post-hoc analysis, Udelson and colleagues segmented patients by cGMP increase – those with increases <20% generally had a greater placebo-adjusted geometric mean percent change in NT-proBNP by week 12. This was consistent across all 3 treatment arms, suggesting that smaller increases in cGMP corresponded with reductions in NT-proBNP across all dosing levels. Additionally, similar results were obtained using thresholds of 15% and 10% increase in plasma cGMP.

“No matter what we find, it generates a hypothesis, and we’re using that,” Udelson said. “We will test that hypothesis in the next trial, and there are already plans being made to do this trial and to study a lower dose range based on this finding. So, the next step is testing the hypothesis.”

Editors’ Note: Udelson reports disclosures with Abiomed, Alleviant, Cardurion, Cytokinetics, Medtronic, Merck, and others.

Udelson J, Agladze R, Atkins B, et al. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction: The Cycle-1 REF Trial. Presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026, Phoenix, AZ. October 9-12, 2026.

Cardurion Pharmaceuticals. Cardurion Pharmaceuticals Presents Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, as a Novel Treatment for Heart Failure. October 11, 2026. Accessed October 12, 2026. 

https://cardurion.com/cardurion-pharmaceuticals-presents-phase-2-results-for-tovinontrine-crd-750-a-pde9-inhibitor-as-a-novel-treatment-for-heart-failure/

Cardurion Pharmaceuticals. A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF) (Cycle-1-REF). ClinicalTrials.gov Identifier: NCT06215911. Updated September 1, 2026. Accessed October 12, 2026. 

https://clinicaltrials.gov/study/NCT06215911

Videos

James Udelson, MD, discusses the results of the Cycle-1-REF study, presented at HFSA 2026, that could support an inverse dose-response relationship with this PDE9 inhibitor.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Doris Quon, MD, PhD, is the medical director of the Orthopaedic Hemophilia Treatment Center at the Orthopaedic Institute for Children in Los Angeles.

Physical activity, which many adults with hemophilia A were kept from as children, may now be part of protecting their joints, according to Doris Quon, MD, PhD, medical director of the Orthopaedic Hemophilia Treatment Center at the Orthopaedic Institute for Children in Los Angeles, in an interview with 

. Quon believes the goal of care has moved past bleed prevention toward a fuller life, though older patients with established joint damage still face gaps.

“They never grew up with these non-factor therapies, and even with factor, they had breakthrough bleeds, and they felt that they couldn’t do the things other kids could do,” Quon said.

Off the Sidelines: Exercise in Hemophilia A, With Doris Quon, MD, PhD

Physical Activity and Joint Stability in Hemophilia A

Quon primarily treats adults, and some were kept out of sports entirely as children because of bleeding concerns. That approach has reversed. Quon’s team now encourages physical activity, since in her view well-developed muscles around the joints help stabilize them.

“The healthier the muscle around the joints, the less joint bleeding you actually have,” Quon said.

A Cochrane review of small trials in people with hemophilia found exercise groups saw greater improvements in pain, muscle strength, and joint range of motion than control groups, though none of the included studies reported bleed frequency as an outcome.¹

Hemophilia A Treatment Goals From Childhood to Adulthood

Quon described priorities shifting across a patient’s life. In childhood, the focus is developing healthy joints. In adolescence, care centers on maintaining joint health while helping patients become more independent with their treatment and learn to choose appropriate activities.

By adulthood, she sees the goal as patients doing what they want without limits from their condition. Travel has become a major priority for many adults, and Quon noted patients no longer need to bring suitcases full of factor. Patients have told her caring for a family has also become easier.

“Your treatment is not such a burden anymore,” Quon said.

Subclinical Bleeding and Chronic Pain Remain an Unmet Need

In Quon’s view, the unmet need in hemophilia A care has shifted. Breakthrough bleeds once dominated, but she now sees less of those and more difficulty identifying subclinical bleeding and distinguishing a bleed from chronic pain.

That challenge is sharpest in older patients with acute pain layered on top of chronic arthropathy pain. Researchers have noted physical examination and patient self-assessment may not accurately identify a joint bleed, and teams are developing artificial intelligence tools paired with point-of-care ultrasound to support detection at the bedside and at home.²

Quon expects the next generation to face this problem less often.

“Even zero bleeds doesn’t always mean healthy joints,” Quon said. “As kids grow up with no bleeding, they’ll have healthier joints and have much better function, and I think that means a lot.”

Editors’ Note: Disclosures for Quon include Bayer, BioMarin, and Sanofi.

Strike K, Mulder K, Michael R. Exercise for haemophilia. 

https://www.cochrane.org/evidence/CD011180_exercise-people-haemophilia

Tyrrell PN, Alvarez-Román MT, Bakeer N, et al. Utilizing artificial intelligence for the detection of hemarthrosis in hemophilia using point-of-care ultrasonography. 

How patient priorities shift from childhood to adulthood, and why separating subclinical bleeds from chronic pain remains an unmet need.

Hematology

Starting systemic-ready patients with uncontrolled atopic dermatitis on systemic therapy, often a biologic, matters more than which agent comes first.

Comparing IL-13–targeting biologics means weighing trial design, populations, outcomes, and safety, then putting it in real-world terms.

Oral targeted agents, multispecific antibodies, and unconventional targets lead the atopic dermatitis pipeline.

 who remain uncontrolled on topical therapy, getting them onto systemic treatment matters more than which biologic a clinician selects first, according to Raj Chovatiya, MD, PhD, associate professor at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, Illinois.

Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD

2026 Fall Clinical Dermatology Conference

 in Las Vegas, Nevada, where he joined April W. Armstrong, MD, MPH, and Elizabeth (Lisa) A. Swanson, MD, for a satellite symposium titled “Better Biologic Decision-Making for Moderate-to-Severe Atopic Dermatitis: An Interactive Expert Exchange.”

 The session addressed the current biologic landscape in atopic dermatitis and how clinicians can make treatment decisions using the available evidence.

How Should Clinicians Approach Biologic Selection in Atopic Dermatitis?

Chovatiya’s first message centered on action over perfection. Clinicians may have many valid reasons for choosing one biologic over another, but he emphasized no wrong answer exists as long as a patient ready for systemic therapy is started on one. For many of these patients, the appropriate next step will be a biologic, and helping them move past persistent disease on topicals is a meaningful clinical gain.

How Do the IL-13–Targeting Biologics Compare?

His second point focused on interpreting the evidence behind current options. Clinicians now have more biologic choices in atopic dermatitis than ever before, which can make selection difficult on paper, particularly among agents acting on interleukin (IL)-13 signaling: dupilumab (Dupixent), tralokinumab (Adbry), and lebrikizumab (Ebglyss). Dupilumab blocks the shared IL-4 receptor alpha subunit, inhibiting both IL-4 and IL-13 signaling, while tralokinumab and lebrikizumab target IL-13 directly.

Without comprehensive head-to-head data, Chovatiya stressed the importance of comparing these agents directly where possible and indirectly otherwise, with attention to differences in trial design, patient populations, outcomes of interest, and safety. He also underscored the need to translate those comparisons into real-world terms, equipping both clinician and patient to reach the best possible treatment choice.

What Emerging Therapies Are on the Horizon for Atopic Dermatitis?

Therapeutic innovation in atopic dermatitis has not slowed over the past decade, Chovatiya noted, pointing to late-breaking presentations at the European Academy of Dermatology and Venereology (EADV) Congress 2026, held September 30 to October 3 in Vienna, Austria.<sup>2</sup> He highlighted 3 themes shaping the field.

The first is convenience, with a range of oral molecules designed to engage well-validated targets and deliver biologic-like efficacy as a daily oral medication. The second is raising the efficacy ceiling through multispecific antibodies, including bispecific and trispecific agents combining established and novel targets in a single therapy to safely and effectively improve treatment response.

The third theme involves targets well outside the conventional atopic dermatitis framework. Although these pathways may not yet be household names, Chovatiya suggested they could allow clinicians to safely and effectively treat more patients and potentially change the course of disease.

Editor's Note: This transcript has been edited for grammar and clarity using artificial intelligence tools. Chovatiya previously reported serving as an adviser, consultant, speaker, and/or investigator for AbbVie, Amgen, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi, Sitryx, and UCB.

Armstrong AW, Chovatiya R, Swanson EA. Satellite symposium: better biologic decision-making for moderate-to-severe atopic dermatitis: an interactive expert exchange. Presented at: Fall Clinical Dermatology Conference 2026; October 8-11, 2026; Las Vegas, NV.

EADV Congress 2026. European Academy of Dermatology and Venereology. September 30-October 3, 2026. Vienna, Austria.

Raj Chovatiya, MD, PhD, explains how to approach biologic selection in atopic dermatitis and previews oral, multispecific, and novel-target therapies.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Eugenia Shmidt, MD, is Associate Professor at the University of Minnesota, where she serves as the Co-Director of the IBD Program.

Zoë Gottlieb, MD, Assistant Professor in the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai and The Susan and Leonard Feinstein Inflammatory Bowel Disease Center.

 who underwent intrauterine insemination (IUI) or embryo transfer (ET) achieved pregnancy, according to prospective data from the WIsDoM cohort presented at the 

American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting

 in Nashville, Tennessee. Success varied sharply by treatment modality.

Co-first authors Eugenia Shmidt, MD, of the University of Minnesota, and Zoë Gottlieb, MD, of the Icahn School of Medicine at Mount Sinai, discussed the findings in an interview with 

IVF vs IUI in IBD: Embryo Transfer Success in the WIsDoM Study

IBD frequently affects women during their reproductive years, and both active disease and prior pelvic surgery have been linked to reduced fertility.2 In a meta-analysis, ileal pouch-anal anastomosis in women with ulcerative colitis was associated with a roughly threefold increase in infertility risk, from 15% to 48%.

 The 2025 Global Consensus Statement on pregnancy in IBD suggests that assisted reproductive technology (ART) appears similarly effective in women with and without IBD, but prospective data have been scarce.

Gottlieb explained that most existing evidence comes from retrospective questionnaires subject to recall bias, or from large databases that miss nuances in individual care. WIsDoM was designed to follow women in real time through their attempts to conceive. The registry enrolls women aged 18 to 45 years who plan pregnancy within 15 months, at more than 30 US and Canadian sites, and collects monthly surveys that are adjudicated against medical records.

Who Used Fertility Treatment and How Often It Worked

In the dataset presented at ACG, of 421 participants, 67 underwent fertility treatment. Compared with women who did not, they were older (median age, 34 vs 32 years; 

 <.001) and had attempted conception longer (median, 11 vs 2 months; 

 <.001). They were also more likely to have had prior pelvic IBD surgery (16.4% vs 5.4%; 

 = .01). Active disease was numerically more common in the fertility treatment group (56.7% vs 43.5%; 

Among 52 women who attempted pregnancy with IUI, ET, or both, 38 (73%) conceived. Across 97 individual attempts, 73% of ET attempts resulted in pregnancy, compared with 10% of IUI attempts (adjusted OR, 44; 95% CI, 8.9-221; 

 <.001). Disease activity and prior IBD surgery were not significantly associated with success. All 7 women with prior pelvic surgery who underwent ET conceived, while neither of the 2 who tried IUI alone did.

Shmidt noted that this subgroup is too small for statistical conclusions. Even so, she said the results suggest women with prior pelvic surgery may benefit from going directly to ET rather than delaying with unsuccessful IUI cycles. Gottlieb said the gap between ET and IUI was considerably wider than in the general population. She added that cost and insurance barriers to ET deserve attention, because repeated failed IUI cycles take both a financial and an emotional toll.

Fertility Counseling and Referral Timing in IBD

Shmidt encouraged gastroenterologists to raise family planning early. She cited consensus guidance recommending referral to a fertility specialist after 6 months of attempted conception.

 She said women older than 40 years should be referred after 3 months, and she suggested a similarly early referral after rectal dissection.

The Women with Inflammatory Bowel Disease & Motherhood (WIsDoM) Study

Voluntary childlessness has been reported in 18% of women with Crohn disease and 14% of those with ulcerative colitis, compared with 6.2% in the general population.

 Gottlieb said this is one reason counseling matters, and she noted that WIsDoM is still enrolling to broaden the diversity of its cohort.

Editors’ note: Shmidt reports relevant disclosures with Celgene and Takeda. Gottlieb reports no relevant disclosures.

Shmidt E, Gottlieb ZS, Evans M, et al. Assisted reproductive technology outcomes in women with inflammatory bowel disease: prospective data from the WIsDoM cohort. Presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN.

Mahadevan U, Seow CH, Barnes EL, et al. Global consensus statement on the management of pregnancy in inflammatory bowel disease. 

Waljee A, Waljee J, Morris AM, Higgins PDR. Threefold increased risk of infertility: a meta-analysis of infertility after ileal pouch anal anastomosis in ulcerative colitis. 

Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. 

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer. 

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Fertility Treatment in IBD: Insights From the WIsDoM Cohort

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction-associated steatohepatitis (MASH)

 and hepatic fibrosis who received resmetirom had lower rates of major adverse cardiovascular events (MACE) and all-cause mortality than matched patients receiving semaglutide, according to findings from a real-world analysis presented at the 

The poster, presented by Jalal Samhoun, MD, Florida Atlantic University, addresses a gap the investigators identified: there are no comparative cardiovascular outcome data between the 2 therapies, even though cardiovascular disease contributes heavily to morbidity and mortality in MASLD and MASH.

How Resmetirom and Semaglutide Compare for MASH With Fibrosis

Resmetirom is an oral, liver-directed, thyroid hormone receptor-β agonist. In March 2024, the US Food and Drug Administration (FDA) granted it accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis. It was the first drug approved for the disease. In the phase 3 MAESTRO-NASH trial, MASH resolution without worsening of fibrosis occurred in 25.9% and 29.9% of patients receiving resmetirom 80 mg and 100 mg, respectively, versus 9.7% with placebo. Low-density lipoprotein cholesterol fell by 13.6% and 16.3% at week 24.

Semaglutide 2.4 mg received accelerated approval for the same population in August 2025 based on part 1 of the phase 3 ESSENCE trial, in which 62.9% of patients receiving semaglutide achieved steatohepatitis resolution without worsening of fibrosis, versus 34.3% with placebo.

 Unlike resmetirom, semaglutide has a dedicated cardiovascular outcome trial. In SELECT, it reduced MACE by 20% versus placebo in adults with established cardiovascular disease and 

TriNetX Study Design and Cardiovascular Outcomes With Resmetirom

Investigators used the TriNetX Global Collaborative Network to identify adults with MASLD or MASH and hepatic fibrosis receiving resmetirom or semaglutide. They performed 1:1 propensity score matching on demographics, cardiovascular risk factors, metabolic comorbidities, liver disease characteristics, medications, and laboratory values.

The final cohorts included 4253 patients each. The primary outcome was MACE, defined as myocardial infarction (MI), ischemic stroke, or all-cause mortality. Secondary outcomes were all-cause mortality, MI, atrial fibrillation (AF), and 

At 1 year, resmetirom was associated with lower risks of MACE (hazard ratio [HR], 0.50; 95% CI, 0.32-0.80; 

 = .003), all-cause mortality (HR, 0.29; 95% CI, 0.16-0.54; 

 <.001), and HF (HR, 0.64; 95% CI, 0.42-0.99; 

 = .04). The 2 groups did not differ significantly in MI or AF.

At 2 years, the lower risks of MACE (HR, 0.61; 95% CI, 0.41-0.89; 

 = .01) and all-cause mortality (HR, 0.33; 95% CI, 0.20-0.55; 

 <.001) persisted. AF showed a nonsignificant trend favoring resmetirom (HR, 0.66; 95% CI, 0.41-1.07; 

What the Resmetirom Findings Mean and What Remains Unknown

Investigators described the findings as early real-world evidence that resmetirom may confer cardiovascular benefits beyond its established hepatic effects. The lower risks they observed emerged within the first year and persisted through 2 years of follow-up.

The analysis is retrospective and drew on electronic health records, so it can show associations but cannot establish causation. Propensity matching accounts only for variables recorded in the database, and residual confounding cannot be excluded. All-cause mortality was included in the MACE composite, while rates of MI did not differ between groups.1 Additionally, semaglutide has shown cardiovascular benefit in a randomized trial, but no randomized cardiovascular outcome data for resmetirom have been published.

Samhoun J, et al. Cardiovascular outcomes of resmetirom versus semaglutide in patients with MASLD/MASH: a propensity-matched real-world analysis. Presented at: American College of Gastroenterology 2026 Annual Scientific Meeting; October 9-14, 2026; Nashville, TN.

Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. 

Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. 

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. 

Articles

A propensity-matched TriNetX analysis presented at ACG 2026 found lower MACE and mortality with resmetirom vs semaglutide over 2 years in MASLD/MASH.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Resmetirom Tied to Lower MACE vs Semaglutide in Real-World MASLD Analysis

Evan Dellon, MD, MPH, is a professor in the division of gastroenterology and hepatology and director of the Center for Esophageal Diseases and Swallowing at UNC School of Medicine.

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Dupilumab Improves Esophageal Distensibility in EoE: REMODEL Trial 

Volixibat reduced itch scores vs placebo in patients with PSC and moderate to severe pruritus in the phase 2b VISTAS trial presented at ACG 2026.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Volixibat Reduces PSC-Related Pruritus in Phase 2b VISTAS Trial

A treatment center director explains how point-of-care ultrasound separates subclinical bleeds from chronic joint pain.

Hemophilia A Care Beyond Zero Bleeds, With Doris Quon, MD, PhD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Topline phase 3 ALOFT-IPF data show admilparant 60 mg improved 52-week FVC vs placebo in IPF, while the 120 mg dose missed statistical significance.

Pulmonary Fibrosis

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Mary Spellman, MD, chief medical officer, Rubedo Life Sciences

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

RLS-1496 Cream Reduces Actinic Keratosis Lesions 

Post hoc FORTIFY OLE analyses presented at ACG 2026 show sustained remission across disease locations and rising no-draining-fistula rates over 5 years.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Topline data show a 69% placebo-adjusted drop in serum bile acids, with an sNDA planned for the first half of 2027.

Maralixibat Eases Cholestatic Pruritus in Phase 3 EXPAND Trial

As the EoE treatment landscape expands, new therapeutic targets may create opportunities for more individualized care. The panel closes the series by connecting emerging science with practical principles for improving long-term EoE management.

Video Series

Emerging Therapies and the Future of EoE Care

Access can determine whether an effective EoE treatment plan becomes a reality. The expert faculty discuss practical strategies for navigating coverage, cost, and authorization barriers to support timely care.

Overcoming Treatment Access Barriers in EoE

Jennifer Hsiao, MD, discusses HS treatment expectations, biologic selection, oral JAK inhibitors, and comorbidity screening.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Latest News

Tovinontrine Reduces NT-proBNP in HFrEF, May Have Greater Benefit at Smaller Doses

Off the Sidelines: Exercise in Hemophilia A, With Doris Quon, MD, PhD

Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD

Fertility Treatment in IBD: Insights From the WIsDoM Cohort

Resmetirom Tied to Lower MACE vs Semaglutide in Real-World MASLD Analysis